AtriCure, Inc.
NASDAQ•ATRC
CEO: Mr. Michael H. Carrel
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 2005-08-05
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
連絡先情報
時価総額
$1.51B
PER (TTM)
-127.0
58.6
配当利回り
--
52週高値
$43.18
52週安値
$28.29
52週レンジ
順位67Top 97.6%
1.4
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1.4 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$140.50M+0.00%
直近4四半期の推移
EPS
$0.04+0.00%
直近4四半期の推移
フリーCF
$23.43M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Revenue Growth Strong Worldwide revenue reached $534.53M, increasing 14.9% driven by open ablation and pain management product lines.
Net Loss Significantly Narrows Net loss improved to $(11.45)M from $(44.70)M, reflecting a $33.25M improvement in operating results.
Gross Margin Expansion Gross margin rose to 75.0% due to a more favorable product mix offsetting increasing product costs.
New Product Adoption Drives Growth Launches like cryoSPHERE MAX probe and AtriClip FLEX-Mini meaningfully contributed to revenue growth in 2025.
リスク要因
Market Acceptance Uncertainty Failure to achieve widespread U.S. market acceptance harms operating results and achieving sustained profitability targets.
Intense Competition Pressures Intense competition and new product introductions may decrease market share, causing revenue decline and margin compression.
Clinical Trial Regulatory Hurdles Clinical trial delays or failure to satisfy FDA requirements slow adoption and commercialization efforts for new indications.
International Distribution Reliance Reliance on independent distributors in international markets creates vulnerability to sales disruption and performance variability.
見通し
R&D Pipeline Advancement Continue investing in R&D for new technologies, including initiating clinical trials for the novel PFA dual energy platform.
Clinical Science Expansion Support expanded labeling claims via landmark trials like LeAAPS enrollment completion and BoxX-NoAF patient enrollment.
Global Commercial Expansion Pursue global commercial expansion across all franchises, leveraging recent product launches like cryoXT and PRO-Mini.
Opportunistic Acquisition Strategy Remain opportunistic regarding acquisitions based on product innovation, clinical differentiation, and strategic financial criteria evaluation.
同業比較
売上高 (TTM)
$5.45B
$2.73B
$1.17B
粗利益率 (最新四半期)
100.0%
96.6%
77.8%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| TWST | $2.98B | -38.8 | -16.6% | 28.8% |
| TXG | $2.76B | -63.2 | -5.7% | 15.1% |
| LMAT | $2.41B | 41.8 | 15.6% | 30.1% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
4.4%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい
深度リサーチ
次回決算:2026年4月27日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし